Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCCG CNSGCT2021 trial in newly diagnosed central nervous system germ cell tumors
jRCTs051220066Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carboplatin, etoposide, cisplatin, cyclophosphamide, methotrexate and 2 more in intracranial germ cell tumor (ICGCT) and germinoma (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 5-year progression-free survival rate. Started Oct 2022; status: recruiting.
02
Drugs
carboplatinetoposidecisplatincyclophosphamidemethotrexate
03
Conditions
intracranial germ cell tumor (ICGCT)germinoma
Beyond the preview
Go deeper on jRCTs051220066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220066.